Pure Global

Efficacy and Safety of HRS-7535 Tablets in Obese Subjects . - Trial NCT06250946

Access comprehensive clinical trial information for NCT06250946 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shandong Suncadia Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Overweight and Obesity. Target enrollment is 225 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06250946
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06250946
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in Obese Subjects

Study Focus

Overweight and Obesity

HRS-7535;Placebo

Interventional

drug

Sponsor & Location

Shandong Suncadia Medicine Co., Ltd.

Timeline & Enrollment

Phase 2

Feb 01, 2024

Feb 01, 2025

225 participants

Primary Outcome

Percent change in body weight from baseline at Week 26

Summary

The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in Chinese Obese
 Subjects.

ICD-10 Classifications

Obesity
Other obesity
Obesity due to excess calories
Obesity, unspecified
Obesity and other hyperalimentation

Data Source

ClinicalTrials.gov

NCT06250946

Non-Device Trial